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Cyclosporine A (CsA) is widely used as an immunosuppressant for the treatment of autoimmune diseases 
and immune regulation in transplant patients. Due to its wide applicability, studies of unwanted side 
effects of CsA are imperative. It has been found that not all patients treated with CsA display the same 
types/patterns of adverse effects. To ascertain the bases for these differential responses, potential differing 
effects of CsA on B-lymphocytes were analyzed. This entailed an assessment of changes in CsA viability 
and mitotic activity within splenocyte populations from BALB/c and ICR mice. These particular strains 
were examined because: (1) in each of them, previously have been shown that differed in the respond to 
biological response modifiers, such as bacterial agents, and/or immunogens; (2) our own earlier studies 
showing strain-associated differences in ex vivo splenocyte/lymphocyte responses to other drug; and, 
(3) a potential immunomodulatory effect of any agent should be studied in at least two different strains 
during a broad toxicological evaluation. Splenocytes from each strain were treated with 200 μg/mL 
CsA, and CD4+, CD8+, and CD19+ cell viabilities were monitored at various time points during the 
exposure period. In general, there appeared to be a trend toward greater decreases in viability among 
BALB/c B-lymphocytes than their ICR counterparts as incubation progressed. Differences related with 
T-lymphocyte sensitivity to drug associated to strains was not observed, because it was uniformly lethal 
throughout. With regard to mitotic activity, cells from ICR mice were more susceptible to inhibition of 
spontaneous cell division at low concentrations of CsA (relative to the rates of blastogenesis by BALB/c 
counterparts). At higher concentrations of the drug however, there were no differences in the sensitivity 
of each strain. This work provides new insight into the mechanism of action of CsA and illustrates the 
need for at least two different strains of mice/rodents for the evaluation of the overall toxicological 
potential of any test agent.
Uniterms: Immunotoxicity. Cyclosporine A/immunomodulatory effects. Cyclosporine A/ adverse effects. 
B-lymphocytes. BALB/c ICR. Blastogenesis.
Ciclosporina A (CsA) é amplamente usada como imunossupressor para o tratamento de doenças 
autoimunes e regulação imune nos pacientes transplantados. Devido à alta aplicabilidade, são imperativos 
os estudos sobre seus efeitos colaterais indesejáveis. Descobriu-se que nem todos os pacientes tratados 
com CsA apresentam os mesmos tipos/padrões de efeitos adversos. Para averiguar as bases dessas 
respostas diferentes, analisaram-se efeitos potenciais diferentes da CsA nos linfócitos B. Isto envolveu 
a avaliação de alterações na viabilidade da CsA e da atividade mitótica dentro das populações de 
esplenócitos de camundongos BALB/c e ICR. Essas espécies, em particular, foram examinadas porque: 
(1) cada uma delas mostrou, previamente, respostas diferentes a modificadores de respostas biológicas, 
tais como agentes bacterianos e/ou imunogênicos; (2) nossos estudos anteriores mostraram diferenças 
associadas às espécies em respostas ex vivo de esplenócitos/linfócitos a outro fármaco e (3) qualquer 
efeito imunomodulatório potencial de um agente em teste deveria ser estudado, no mínimo, em duas 
espécies diferentes durante a avaliação toxicológica ampla. Esplenócitos de cada espécie foram tratados 
com 200 µg/mL de CSA e a viabilidade das células CD4+, CD8+ e CD19+ foi monitorada em vários tempos 
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durante o período de exposição. No geral, parece haver uma tendência em relação a aumentos maiores 
na viabilidade entre os linfócitos B de BALB/c do que no de ICR, à medida que a incubação progride. 
Não se observou diferenças na sensibilidade do linfócito T, uma vez que o fármaco foi uniformemente 
letal. Com relação à atividade mitótica, as células de camundongos ICR se mostraram mais suscetíveis 
à inibição da divisão celular espontânea em baixas concentrações de CsA (relativamente às taxas de 
blastogênese de BALB/c). Em concentrações maiores do fármaco, entretanto, não houve diferenças na 
sensibilidade em cada uma das espécies. Este trabalho propicia nova visão do mecanismo de ação de 
CsA e ilustra a necessidade de, pelo menos, duas espécies diferentes de camundongos/roedores para a 
avaliação da toxicidade potencial de qualquer agente em teste.
Uniterms: Imunotoxicidade. Ciclosporina A/efeito imunomodulatório. Ciclosporina A/efeitos adversos. 
Linfócitos B. BALB/c. Blastogênese.
immuno-suppression maintenance scheme (Waiser et al., 
2006). CsA is able to inhibit the production of interleukin 
(IL)-2 and suppresses the expression of its receptor (i.e., 
CD25) in cytotoxic T-lymphocytes (Hess et al., 1986). In 
addition, CsA blocks T-helper lymphocyte activation, re-
sulting in decreased cytokine production from this critical 
cell sub-population (Thomas, Gordon, 1986).
CsA is a cytotoxic agent for leukemia cell lines, where 
it mainly triggers apoptosis. In viability assays, it has been 
shown that CsA-induced cell death is dependent on the 
concentration and length of exposure. Secondary effects ob-
served are: lower cell proliferation, an increase in frequency 
of Anexin V+ cells, and release of cytochrome c. Although 
many studies have provided insight about CsA’s mechanism 
of action in CD4+ and CD8+ sub-populations (Diaz-Romero 
et al., 2001), the effect of the drug on B-lymphocytes 
(CD19+ cells) has not been precisely determined and only 
a few studies on this issue are available in the literature (see 
Healy et al., 2006 or Gary-Gouy et al., 2006).
Based on the fact that mice have been used in immu-
notoxicology studies due largely to their well-characterized 
immune systems, in the present study, it was decided to ana-
lyze the immunomodulatory potential of CsA in splenocytes 
from two murine strains (i.e., BALB/c and ICR), with a 
specific focus on its effects upon CD19+ cells. The first goal 
of these particular studies was to confirm our earlier hypoth-
esis, which held that in order for investigators to effectively 
evaluate the potential immunotoxicity of any formulation, 
at least two different strains of mice are needed, depending 
on the genetic, phenotypic and functional background of 
the mice strain used. The second goal was to assess T-cell-
independent CsA immunotoxicity in these mice.
MATERIAL AND METHODS
Mice
Nine ICR (Pharmacy Department Biotherium, 
Universidad Nacional de Colombia) and eleven BALB/c 
INTRODUCTION
Cyclosporine A (CsA), a metabolite derived from the 
fungus Tolypocladium inflatum gams (Cohen et al., 1984; 
Kahan, 1985; Thomas, Gordon, 1986), known as a im-
munosuppresive agent (Kahan, 1985; Fukuzawa, Shearer, 
1989; Flores et al., 2004; Rezzani et al., 2006; Waiser et 
al., 2006) used to prevent host versus graft responses in pa-
tients subjected to heart, liver, kidney, bone marrow, and/or 
pancreas transplants (Ptachcinski et al., 1985; Thomas, 
Gordon, 1986). It has also been used for the treatment of 
autoimmune disorders (Kahan, 1993; Roy et al., 2006) and 
lymphoproliferative diseases (Foa et al., 1981; Gabor et 
al., 1996; Sairanen et al., 2005). CsA’s wide applicability 
makes the study of its mechanism of action, pharmacody-
namics, and unwanted side effects, imperative. Some of the 
unwanted adverse effects reported include nephrotoxicity 
and hepatotoxicity (Canafax, Ascher, 1983), hirsutism, and 
neurologic complications (Ptachcinski et al., 1985). In gen-
eral, these toxic effects have been attributed to cell damage/
death in the target organs (Roy et al., 2006).
Use of this drug in different immunological studies 
has also allowed many of the complex inter-cellular in-
teractions involved in immune responses to be elucidated 
(Hess et al., 1986). At the cellular level, CsA binds to 
Cyp-M (a cyclophilin-family protein), forming a complex 
that interacts to inhibit calcineurin phosphatase activity. 
Currently, many regulatory molecules are believed to be 
suppressed by CsA, including myc and tyrosine kinases 
(among others), leading to disruption of the pathways un-
der their respective control (Roy et al., 2006). On the other 
hand, CsA is able to affect different T-lymphocyte popula-
tions selectively. Its activity does not cause myelosuppres-
sion (Canafax, Ascher, 1983; Ptachcinski et al., 1985); 
it does however, notably alter growth factor production 
(Kahan, 1993). In cell cultures from renal allograft recipi-
ents, concentrations of TGF-β1 and its receptors (Type I 
and II) in supernatants, as well as lymphocyte prolifera-
tion, were higher when CsA was included in a patient’s 
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(Instituto Nacional de Salud Biotherium) 4-week-old 
female mice were used in this study. Female mice were 
used as they are less aggressive than males and therefore 
less prone to cause skin injuries to one another, injuries 
that would hamper immune function evaluation(Vahter 
et al., 2007). Animals were kept in groups of three per 
cage while one cage (group of BALB/c mice) contained 
five individuals. During the experiments, the mice were 
provided with a standard pellet diet (Rodentina, Purina 
S.A., Bogotá, Colombia) and water ad libitum. All expe-
riments were approved by the Ethics Committee of the 
Fundación Instituto de Inmunologia de Colombia. All mice 
were handled according to the procedures required by the 
Colombian Ministry of Social Protection (Resolution No. 
008430 of 1993).
Obtention of splenocytes
Mice were sacrificed by cervical dislocation, ac-
cording to the rules issued by the Department of Phar-
macy of the Faculty of Science, Universidad Nacional 
de Colombia. Each mouse spleen was then aseptically 
removed, placed in a Petri dish containing RPMI 1640 
(GIBCO, Scotland, UK) supplemented with 10% fetal 
bovine serum (FBS), and single cell suspensions were 
prepared by syringe-mediated disaggregation. Mono-
nuclear splenocytes were then separated via a Ficoll-
Hypaque density gradient (ρ = 1.077; ICN Biomedical 
Inc., Aurora, OH).
CsA treatments
Splenocyte cultures were used for the analysis of 
CD4+ (T-helper lymphocyte), CD8+ (cytotoxic T-lym-
phocyte), and CD19+ (B-lymphocyte) expression kinetics 
after CsA exposure. To assess subpopulation mortality, 
aliquots of cells were divided into four subgroups: one 
for the analysis of baseline subpopulation frequencies 
(i.e., markers measured immediately in duplicate samples 
from each mouse) and the remaining three for the study 
of the effects on splenocyte marker expression/mortality, 
after 24, 48, or 72 hr of culture in the presence of the drug. 
Specifically, 4 x 105 cells/well (pre-counted in Neubauer 
Chambers in duplicate wells) were placed in 24-well 
dishes and then received 200 µg of CsA/mL medium 
(Sandimmune, Novartis Pharma AG, Basel, Switzerland); 
time-matched control wells received medium alone. Only 
this CsA level was used because it is the highest dose found 
previously to induce a specific effect (i.e., inhibition) upon 
Ca2+-ATPase and nitric oxide synthase (NOS) (Hutcheson 
et al., 1995).
Flow cytometric analysis of viability
Splenocytes obtained immediately after splenic 
disaggregation/Ficoll separation (baseline count) and 
after different incubation times with CsA, were labeled 
with antibodies to CD4 (anti-mouse CD4-fluorescein 
isothiocyanate [FITC] conjugate), CD8 (anti-mouse 
CD8-phycoerythrin-[PE]), or CD19 (anti-mouse CD19-
FITC) (DAKO Corp, Carpenteria, CA). To assess viability 
of each population, 7-amino-actinomycin D (7-AAD, 
Pharmingen, San Diego, CA) was employed. Expression 
of these surface markers (and of 7-AAD within each po-
pulation) was monitored by flow cytometry (FACScan, 
Becton Dickinson, San José, CA) every 24 hr during the 
exposures for up to 72 hr. In each analysis, 30,000 events 
were acquired (Pheng et al., 2000, 2002). Results are 
expressed as the mean of all replicates from mice of the 
same strain. CellQuest analyses were used to differentiate 
among the three lymphocyte populations as well as within 
each population (i.e., single positives vs. double-positive 
for marker and 7AAD). 
T- and B-lymphocyte spontaneous blastogenesis 
assay
To assess spontaneous blastogenesis, aliquots of 
harvested splenocytes (T- and B-lymphocytes) from each 
mouse were placed in 96-well plates (5 x 105 cells/well) 
and then exposed (in triplicate) to 400, 200, 100, 50, or 
25 µg CsA/mL with no mitogen; control wells received 
vehicle only. Culture supernatants were collected after 
72 hr of incubation, and the cells then pulsed with 1 µCi 
[3H]-thymidine (Amersham-Pharmacia, Buckingham-
shire, UK)/well in fresh (drug-free) medium. The cultures 
were harvested 16 hr later and incorporated radiation was 
quantified on an LS6500 scintillation counter (Beckman, 
Fullerton, CA). Inverse stimulation indexes (ISI) were 
calculated as the ratio of the mean (of triplicates wells) 
counts per minute (cpm) of cells not cultured with the drug 
to the mean cpm of cells that were incubated with the drug. 
ISI values higher than 2.0 were considered indicative of 
significant inhibition of spontaneous replication due to 
the CsA treatment.
Statistical analyses
The results were analysed using the template created 
with Cell-Quest software (Becton Dickinson). An analysis 
of variance (ANOVA) and a two-tailed Student’s t-test 
were performed in order to determine inter-treatment 
differences (results of treated cells vs. those from CsA-
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free controls). Multiple comparisons were also performed 
with the Tukey test. Results were considered statistically 
significant at a p-value < 0.05.
RESULTS
B-lymphocyte mortality after CsA treatment
In this assay, the activity previously reported for 
CsA on T-helper (CD4+) and cytotoxic T lymphocytes 
(CD8+), was experimentally reproduced (Table I). These 
populations showed mortality greater than 90% by 24 h. 
This effect was observed in both strains. However, the 
effect always tended to be more marked in the first 24 h 
among the ICR cells compared to cells from BALB/c 
mice. Longer incubations led to the complete loss of 
any significant inter-strain differences in this parameter.
In the current studies of the B-lymphocyte (i.e., 
CD19+) sub-population, analyses of the background (i.e., 
control) survival rates of B-lymphocytes across the time-
points assayed showed that there were no inter-strain di-
fferences after any given exposure period. However, while 
it did appear that there was a large (≈ 4-fold), increase in 
mortality among the medium-treated cells of the BALB/c 
hosts as a function of time, this change was found not to 
be statistically significant.
Viabilities among CsA-treated CD19+ cells from the 
BALB/c hosts were decreased (compared to levels in con-
trol medium-treated autologous counterparts) as the length 
of incubation with the drug increased (Table II). Specifi-
cally, the percentages of dead BALB/c B-lymphocytes 
due to co-incubation with the CsA rose from 6.60% at 
48 h to 18.84% at 72 hr. Considering that a large increase 
in mortality was likely due to the incubation process itself 
(see above), it remains to be determined how much of this 
nearly 3-fold increase in relative mortality is attributable 
to the CsA itself, and how much of this increase is merely 
a reflection of building upon the shift in background mor-
tality among the cells, i.e., did the CsA just simply hasten 
the death of already dying cells or did the drug induce 
lethality in outright “healthy” cells?
In contrast to the effects seen with the cells from the 
BALB/c hosts, the effect of CsA on ICR B-lymphocytes 
did not significantly differ from medium-treated coun-
terparts at any timepoint. Furthermore, unlike with the 
BALB/c cells, the percentages of dead B-lymphocytes 
among the ICR splenocyte preparations barely increased 
from 5.11% to 9.68% at the corresponding 48→72 hr 
timepoints. Nevertheless, while there were clear strain-
related differences in the degree of change in viability due 
to the CsA treatment (compared to that attributable to the 
incubation process itself), the results did not indicate that 
there were strain-related differences in susceptibility to 
CsA toxicity at any particular timepoint or over the entire 
incubation period tested.
As several of the inter-strain differences barely mis-
sed being considered significant (i.e., p-values < 0.056), 
these studies have to be repeated with even larger numbers 
of mice to verify the significance of the observed outco-
mes. Nonetheless, it is clear from these results that while 
the relative levels of dead ICR B-lymphocytes due to CsA 
TABLE I - Effects of CsA treatment length on CD4+ and CD8+ 
lymphocyte viability
Treatment 
length
Host strain Medium-only CsAa
24 hr CD4
ICR 97.73 ± 3.51 *3.73 ± 0.59
BALB/c 97.23 ± 2.62 *9.00 ± 1.11
48 hr CD4
ICR 96.66 ± 2.54 *0.33 ± 0.10
BALB/c 94.83 ± 4.30 *0.73 ± 0.21
24 hr CD8
ICR 95.67 ± 2.69 *2.93 ± 0.53
BALB /c 94.68 ± 3.90 *7.67 ± 2.53
48 hr CD8 ICR 95.00 ± 3.69 *0.00 ± 0.00
BALB /c 94.03 ± 1.13 *1.00 ± 0.03
aCsA treatment level = 200 µg/ml. bData corresponding to 
percentage of cells still alive (mean ± SD) at the indicated 
timepoint for each given treatment. Results were obtained using 
the CellQuest Program in the window restricted to indicated cell 
population. *Value significantly different from time-matched 
controls.
TABLE II - Effects of CsA treatment length on B-lymphocyte 
viability.
Treatment
length
Host strain Medium-only CsAa
24 hr
ICR b9.61 ± 9.04 b12.93 ± 7.71
Balb/c 1.97 ± 0.78 11.87 ± 11.26
48 hr
ICR 13.93 ± 16.94 5.11 ± 2.31
Balb/c 1.80 ± 0.47 *6.60 ± 1.85
72 hr
ICR 11.32 ± 8.49 9.68 ± 1.05
Balb/c 7.55 ± 0.20 *18.84 ± 9.54
aCsA treatment used = 200 µg/ml. bData indicate percentages 
of non-viable cells after treatment for the indicated time 
period. Results were obtained using CellQuest Program (Flow 
cytometry) in the window restricted to CD19+ population. 
*Value significantly different from that of corresponding control 
(medium-only) cells.
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treatment remained relatively constant across the time-
frame tested, those from BALB/c hosts displayed a trend 
toward time-related increase. As for now, this suggests 
a possible strain-dependent difference in B-lymphocyte 
susceptibility to the effects of CsA.
Spontaneous blastogenesis among CsA-treated 
splenocytes
Cells were subjected to 72-hr of cell culture with 
CsA at different concentrations with the aim assessed any 
drug-induced effect on spontaneous blastogenesis. Using 
ISI as a measure to reflect this effect, the more likely a 
cell was to spontaneously proliferate in the presence of 
the CsA, the lower the ISI value. Assuming, within each 
strain, a uniform level of spontaneous blastogenesis among 
the remaining viable non-T-lymphocyte cells (see Table 
I) from that strain, the numerator in the ISI calculation 
would remain relatively constant. Thus, any observed shift 
to lower ISI values at higher CsA concentrations would 
indicate that the equation denominator was increasing in 
a concentration-related manner, possibly meaning that 
the cells (i.e. surviving B-lymphocytes, monocytes, etc.) 
displayed an increase in spontaneous blastogenic activity.
As shown in Figure 1, the ISI values associated with 
cells from BALB/c mice remained fairly constant across 
the range of CsA concentrations tested. When the data 
were analyzed among all the different tested concentra-
tions for possible differences due to host strain, only the 
effect from 25 µg CSA/mL (and 12.5 µg/mL; data not 
shown) was significantly pronounced (p < 0.05) among 
the cells from ICR mice. Reasons for the abrupt shift from 
CsA acting as inhibitor of spontaneous ICR splenocyte 
cell division (at the lowest sub-lethal doses tested) to one 
where spontaneous blastogenesis was stimulated (at higher 
and even lethal concentrations), remain to be established in 
our ongoing studies and could be associated with selective 
hormetic response for ICR cells [similar to that reported 
for some antitumoral drugs (Wakabayashi et al., 2010)]. It 
is possible that, for low CsA´s concentrations, processes 
such as apoptosis have been induced, yet for high con-
centrations this effect has been inhibited, explaining the 
increased cellular mortality at lower CsA concentrations,
The effect from the low concentration(s) of CsA 
upon the BALB/c splenocytes (non-T-lymphocyte) spon-
taneous blastogenesis was less evident than on ICR coun-
terparts, suggesting inter-strain differences in sensitivity 
to the drug (discussed below). Further studies are needed 
to determine more precisely what is occurring among the 
cells of each strain during incubation with CsA to give rise 
to this apparent difference in sensitivity.
DISCUSSION
CsA, a drug effective in the prophylaxis and tre-
atment of graft-vs.-host disease after allogeneic trans-
plantation, exhibits a suppressor effect on lymphocyte 
(particularly B-lymphocyte) function. This could be one of 
the causes for the low circulating antibody levels that have 
been documented among CsA-treated patients in some 
clinical studies (reviewed by Sena et al., 2006). Several 
researchers have attempted to ascertain the mechanisms by 
which CsA exerts this effect. Unexpectedly, early studies 
with lymphoblastoid (Epstein-Barr virus transformed B-
lymphocytes) and WEHI-231 (mouse [BALB/c x NZB] 
F1, lymphoma-lymphoblastic) cell lines showed that CsA 
- rather than impacting negatively on these lymphocytes 
- appeared to protect them from Fas receptor-mediated 
(Beatty et al., 1998) and/or ionomycin-induced cell death 
(Genestier et al., 1994).
Unlike the results in these previous studies, we 
report a potential immunosuppressive effect of CsA on 
B-lymphocytes when present among the heterogeneous 
cell populations associated with the spleen. Specifically, 
B-lymphocyte mortality was elevated in splenocytes 
treated ex vivo with CsA. While these outcomes initially 
appeared to occur in a manner seemingly independent 
of the host strain from which the cells were derived, a 
general trend developed over the course of the exposure 
period wherein ICR mouse splenocytes displayed lower 
sensitivity to the underlying lethal effect of CsA than did 
their BALB/c counterparts.
These results suggest potential strain-prone B-lym-
phocyte toxicity due to the greater effect on the viability 
of this cell population in the spleens of BALB/c mice. It 
is possible that some aspect of the genetic background/
FIGURE 1 - Spontaneous splenocyte blastogenic activity in 
cultures bearing different CsA concentrations. Values shown 
are the mean ISI values (± SD; ISI = Inverse Stimulation Index) 
from ICR (n = 9; open bars) and BALB/c (n = 11; solid bars) 
mice/ concentration. *Significant differences between BALB/c 
and ICR strains for CsA effect on cells (at p < 0.05).
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biology of the ICR mice might make their splenocytes (i.e., 
their associated immune cell populations) more resistant to 
any deleterious effects from the CsA. Besides the genetic, 
phenotypic and functional background of the mice strain 
used, which were demonstrated in the time in absence 
of treatment [BALB/c cells increased their spontaneous 
mortality by approximately 6 %, from 48 to 72 hr (from 
1.80 +/-0.47 to 7.55 +/-0.20) which suggests a different 
kinetic of the apoptosis process], the effect of the CsA was 
demonstrated. In other words, the CsA treatment increased 
the effect on the cellular viability in the BALB/c cells, 
with regard to the ICR (evidenced from 24 hr of culture, 
still in absence of treatment). Such contrasting responses 
were not entirely unexpected. Several studies performed 
in vivo or ex vivo using isolated cells have indicated that 
the abilities to respond to biological response modifiers 
(such as select β-D-glucan priming agents; Ohno et al., 
2995), immunogens (such as select plasmid expression 
vectors and their corresponding coded proteins; Ito et al., 
2000), allergens, environmental contaminants (such as 
dust mite antigen ± diesel exhaust particles; Ichinose et 
al., 2004), carcinogens (such as azoxymethane + dextran 
sodium sulfate; Suzuki et al., 2006) and selected bacterial 
pathogens (such as Listeria monocytogenes; Park et al., 
2004) or parasites (such as Plasmodium berghei; Scheller 
et al., 1994) differed among different mice strains, often 
to a very significant degree. Our own recent studies have 
also reported similar strain-associated differences in ex 
vivo splenocyte/lymphocyte responses to drugs such as 
pentamidine isethionate and vancomycin (Plaza et al., 
2007; Salguero et al., 2009). Based on these documented 
differences, it was logical for us to use these two strains 
to determine the basis for the differential types/patterns 
of adverse effect responses being observed in patients 
receiving CsA for the treatment of autoimmune diseases/
immune regulation after transplantation.
Regarding the BALB/c viability data, it is not 
apparent why there should be such a clear difference in 
outcomes compared to those from the above-noted earlier 
studies with CsA. One possible explanation is that the 
approach employed here allowed the drug to simultaneou-
sly affect multiple cell populations, an approach more 
representative of an in vivo scenario. As a result, because 
the splenocytes can constantly interact with one another 
and with different cell (by-)products, apart from any di-
rect effects of CsA on B-lymphocytes, there could also 
be secondary effects attributable to the presence of other 
cell types (i.e., the latter modulate the immunomodulatory 
potential of the drug against resident B-lymphocytes).
Differential CsA immunomodulatory activity against 
splenocytes in situ were also evidenced by differing res-
ponses (reflected by ISI values) of the splenocytes (in 
particular, associated B-lymphocytes) from the BALB/c 
and ICR mice. In this case, the effect was mainly observed 
in ICR mice splenocytes at the lowest (non-lethal) doses of 
concentrations tested (i.e., ≤ 25 μg/ml CsA; ISI >2, indi-
cative of inhibition of normal “spontaneous” replication). 
Cells from BALB/c hosts appeared to display no changes 
in spontaneous blastogenesis regardless of the concentra-
tion of CsA applied over the 72 hr period. Studies to assess 
a concentration-dependency of similar effects in other cell 
types have demonstrated an increase in the percentage 
of G0/G1 cells among CsA-treated kidney cells (Healy et 
al., 1998). These authors suggested that CsA was likely 
inducing some direct effect on cell division rates. Based on 
the results reported here, a similar effect is likely to occur 
among the treated splenocytes.
There are two plausible mechanisms to explain 
the decreases in normal blastogenesis seen here by the 
ICR cells (at the lower CsA concentration). First, these 
shifts can simply be explained by the effect of the drug 
on cell viability (i.e., reduction in the number of live 
cells available to divide). The interstrain B-lymphocyte 
viability differences after 72 hr coculture with CsA 
(≈80% BALB/c vs. ≈90% ICR) can partially explain the 
observed variability in the ISI values at this timepoint, 
bearing in mind that the higher the percentage of viable 
cells, the higher the replicative potential. This suggests 
that the ability of CsA to somehow affect the ability of 
ICR B-lymphocytes to undergo spontaneous division 
seems to be occurring, even among a smaller popu-
lation of live cells. A second possible mechanism for 
the observed effect is related to the release of products 
essential for B-lymphocyte replication. Recalling that 
at the lower concentrations where inhibition of sponta-
neous replication (i.e., higher ISI values) was noted, the 
CsA had little effect on B-lymphocyte viability (data 
not shown). Unlike the higher concentration scenario, 
in which T-lymphocyte populations were near-totally 
eradicated, under the conditions associated with lower 
CsA concentrations, i.e., one in which the near-full spec-
trum of splenic immune cells were now likely available 
(if lethality against T-lymphocytes were concomitantly 
lower than at 200 µg/ml concentration), CsA might now 
be able to also affect B-lymphocyte blastogenesis in an 
indirect manner.
Specifically, it is known that CsA treatment can 
reduce IL-2 production by various immune cell types, 
including T-lymphocytes (Hess et al., 1986; Ho et al., 
1996; Masri, 2003; Kang et al., 2007). An obvious 
critical effect from this would be a reduction in normal 
B-lymphocyte activation as well as in its ability to pro-
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liferate. In addition, it has also been shown that among 
T-lymphocytes (see review by Cohen et al., 1984), effec-
tor and regulatory subtypes were affected differently by 
CsA. In particular, CsA treatment selectively reduced T-
effector (specifically T-helper) lymphocyte proliferation/
function while concurrently giving rise to an increase in 
the relative number of regulatory T-lymphocytes (Tre-
gs) and local production of Treg-inducing cytokines. 
Yates et al. (2007), postulated that this could be the 
consequence of a selective effect of CsA on signaling 
(either at the level of receptor expression or post-receptor 
processing) by IL-2 or other factors (i.e., calcineurin, 
Jun N-terminal kinase/p38) required by Tregs to escape 
from the spontaneous apoptosis occurring during nor-
mal balanced immune responses (Naujokat et al., 2003; 
Boldt et al., 2006). That these cells are known to inhibit 
B-lymphocyte (LPS-induced) proliferation (reviewed 
in Curotto de Lafaille and Lafaille, 2002) allows us to 
suggest that, in response to the lower concentrations of 
CsA, there was likely a decrease in IL-2 being released 
by - and a concurrent increase in the relative number 
(and activities) of Tregs- among the test populations of 
splenocytes examined here, a functional event perhaps 
associated with the hormetic phenomena.
However, the fact that IL-2 is a survival factor ne-
eded to limit apoptosis among Tregs, and that the CsA is 
expected to be inducing a decrease in IL-2 levels, presents 
a challenge to our conclusion. Recent investigations have 
sought to better define other cytokines (apart from IL-2, 
including IL-4, -6, -7, and -15) that are protective against 
apoptosis (see Yates et al., 2007). Future studies in our 
laboratory will be conducted to investigate whether CsA 
treatments cause any changes (i.e., decreases) in the pro-
duction of these other Treg apoptosis-sparing cytokines 
by splenocytes from each mouse strain.
Because the results observed in the blastogenesis 
assays reflect the cumulative results of differential CsA 
activity upon multiple sub-populations in the spleens, 
the true effects of CsA upon each specific lymphocyte 
sub-population are likely to be masked. As for now, it 
remains unclear which (if any) particular lymphocyte 
type is primarily responsible for the results observed in 
the current study. Studies using B-lymphocyte mitogen 
lipopolysaccharide (LPS) are underway to obtain a better 
understanding of CsA effects on the ability of this cell 
type to contribute (or otherwise) to the ISI measurements. 
Furthermore, based on the observations that CsA affected 
B-lymphocyte viability within the splenic populations 
tested, we also believe it is important to more precisely 
determine how the drug affected viability (i.e., by increa-
sing apoptosis or non-apoptotic mechanisms).
CONCLUSIONS
While the specific mechanisms underlying these 
outcomes are not yet clear, it is hoped the finding that cells 
within the ICR mouse splenocyte populations were more 
susceptible to low-concentration CsA than the BALB/c 
splenocytes, and that BALB/c cells appeared more sus-
ceptible to a lethal effect from the drug (first goal), will 
ultimately help to explain why not all patients treated with 
CsA uniformly display the same types/patterns of adverse 
effects. This study has provided preliminary evidence 
related with the ex vivo immunomodulatory activity of 
CsA on critical lymphocyte sub-populations that normally 
reside in the spleen. Moreover, the study has documented 
that CsA exert a cytotoxic effect on splenic CD19+ (B-
lymphocyte) sub-populations, a result previously unrepor-
ted (B-lymphocytes from BALB/c are more susceptible to 
CsA effect than the ICR CD19+ splenocytes, supporting 
the solving of the second goal). Future studies should as-
sess the effect of CsA on cellular mitosis, including that 
after stimulation of T- and B-lymphocyte mitogens.
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